Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Among the emerging targets and biomarkers, Oncostatin M has attracted much interest recently.
Oncostatin M has diagnostic, prognostic, and therapeutic capabilities. High mucosal Oncostatin M predicts primary non-response to Anti-Tumor Necrosis Factor alfa (TNF-alfa) antibodies / Tumor Necrosis Factor alfa (TNF-alfa) inhibitors. However, the question is whether a single cytokine can capture the complexity and heterogeneity of Inflammatory Bowel Disease (IBD). Neutralizing Oncostatin M in patients with elevated mucosal Oncostatin M seems attractive. It should be considered a valid option for the first [biomark…